Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic ki...
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
About this item
Full title
Author / Creator
ASi in CKD group , Tuttle, Katherine R , Hauske, Sibylle J , Canziani, Maria Eugenia , Caramori, Maria Luiza , Cherney, David , Cronin, Lisa , Heerspink, Hiddo J L , Hugo, Christian , Nangaku, Masaomi , Rotter, Ricardo Correa , Silva, Arnold , Shah, Shimoli V , Sun, Zhichao , Urbach, Dorothea , de Zeeuw, Dick and Rossing, Peter
Publisher
England: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Excess aldosterone accelerates chronic kidney disease progression. This phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy, safety, and dose selection.
This was a multinational, randomised, controlled, phase 2 trial. People aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 30 to...
Alternative Titles
Full title
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2903859389
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2903859389
Other Identifiers
ISSN
0140-6736,1474-547X
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(23)02408-X
